Weight-loss drug reduces stroke and heart risk

Weight-loss drug reduces stroke and heart risk A weight-loss drug has been proven to also reduce the risk of a stroke or heart attack, according to a new trial.

The makers of Wegovy, Novo Nordisk, say its latest study shows it cuts risk of a cardiovascular event in overweight people with heart disease by a fifth.

The firm hailed it a "landmark trial", saying it would change the way obesity is regarded and treated.

While the findings still have to be fully reviewed, experts agreed the results were potentially significant. BBC News

See also:

• Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Novo Nordisk
• Wegovy: Weight loss injections can lower heart attack and stroke risk in obese people by a fifth, research suggests Sky News